Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trialMahrukh M. Syeda, David Polsky, Mario Santinami et al.|The Lancet Oncology|2025Cited by 28
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patientsGeorg Lodde, Jürgen C. Becker, Ulrike Leiter et al.|European Journal of Cancer|2025Cited by 9